BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

1:51 PM
 | 
Mar 07, 2019
 |  BC Extra  |  Financial News

Follow-on roundup: Horizon, Apellis, Epizyme

Horizon, Apellis and Epizyme each priced follow-ons raising a total of $552 million.

Horizon Pharma plc (NASDAQ:HZNP) raised $300 million late Wednesday through the sale of 12 million shares at $24.50. The price is a 13% discount to its Monday close of $28.01, when the company proposed the offering after market close. Horizon was up $0.34 to $25.82 on Thursday.

Last month, Horizon said teprotumumab (HZN-001) met the primary and secondary endpoints in...

Read the full 342 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >